ImmunityBio, Inc. (IBRX) Price Target Raised After Strong ANKTIVA Launch

ImmunityBio, Inc. (NASDAQ:IBRX) ranks among the most shorted stocks to buy according to analysts. H.C. Wainwright maintained a Buy rating for ImmunityBio, Inc. (NASDAQ:IBRX) and increased its price target to $15 from $10 on February 23. According to the firm, following ANKTIVA’s U.S. introduction in 2025, ImmunityBio, Inc. (NASDAQ:IBRX) reported that the medication brought in $113 million.

The company also saw a 750% increase in unit sales, with Q4 revenue of $38.3 million, up 20% from the third quarter. Moreover, ImmunityBio, Inc. (NASDAQ:IBRX) has broadened its global reach by teaming with Biopharma and Cigalah Healthcare to commercialize ANKTIVA in Saudi Arabia and the MENA area, after regulatory clearance from the Saudi Food and Drug Authority.

At the same time, ImmunityBio, Inc. (NASDAQ:IBRX) is conducting randomized studies in BCG-naïve non-muscle-invasive bladder cancer. The company plans to submit a Biologics License Application in the fourth quarter of 2026.

ImmunityBio, Inc. (NASDAQ:IBRX) is a U.S. biotechnology company developing next‑generation immunotherapies and vaccines that enhance the natural immune system to fight cancers and infectious diseases.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.